Eli Lilly said on Thursday that India's drug regulator had approved the launch of pre-filled injector pens of its blockbuster ...

In the race to make the most tolerable obesity drug, there seems to be no clear winner—at least not according to analysts ...

The global fight between Eli Lilly and Novo Nordisk for dominance in the red-hot weight-loss drug market is shifting to India ...

Eli Lillys Mounjaro KwikPen gains approval in India, targeting diabetes and obesity with its dual-action formula for weight ...

Eli Lilly faces market headwinds, slowing growth, and rising competition. Discover why now might be the time for LLY ...

Eli Lilly's bimagrumab led to weight loss that was due almost entirely to fat reduction when combined with semaglutide, ...

Eli Lilly isn't a one-trick pony. The company's lineup of approved medicines features blockbusters like Verzenio, a cancer ...

Novo Nordisk is seen as having fallen behind in the race for new obesity drugs. It argues it is playing the long game.

Eli Lilly, Novo Nordisk and Amgen release weight loss drug data as competition heats up in the market, while Abridge ...

Novo Nordisk reported mostly mild side effects from its experimental weight-loss drug CagriSema, though results upset ...

By Rishika Sadam and Kashish Tandon HYDERABAD (Reuters) -Danish drugmaker Novo Nordisk launched its blockbuster weight-loss ...

Novo Nordisk launches Wegovy in India, expanding GLP-1 obesity drug market. The product competes with Eli Lilly's Mounjaro ...